ASH 2024 – Shirley D’Sa

Shirley D’Sa highlights the ASPEN trial’s key insights on durable responses with zanubrutinib monotherapy in Waldenström’s macroglobulinemia, explores promising results for the radiopharmaceutical iopofosine in pretreated patients, and shares real-world data from the global registry WhiMSICAL on how therapies impact patients’ quality of life.

Here is the full ASH 2024 report.